- Global Pharma News & Resources

Oxytocic Pharmaceuticals Market Is Set to Expand at A CAGR Of 7.74% To Reach US$ 207.80 Million During the Forecast Period 2021-2031

Increasing childbirth using labor induction is expected to be the key factor driving the growth of oxytocic pharmaceuticals market. As per FMI, growing awareness regarding C-section and its related benefits across the globe has spurred the demand for synthetic oxytocin.

The market will exhibit stellar growth as the prevalence of post-partum hemorrhage continues to increase across the globe. As per the study, oxytocic pharmaceuticals sales will continue rising at 7.74% CAGR between 2021 and 2031.

Additionally, fast-track approvals by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and others are propelling growth in the oxytocic pharmaceuticals market.

The incidence of post-partum hemorrhage is increasing in developed countries due to growing rate of obesity and consumption of tobacco. This might result in heavy bleeding during labor, which is a major factor spurring the adoption of synthetic oxytocin.

According to Future Market Insights, a majority of medical professionals are adopting intravenous administration of oxytocic pharmaceuticals, which will account for over 2/5th of global sales over the next 10 years.

Request Sample Report @

Increasing demand for induced labor and growing cases of post-partum hemorrhage will spur the adoption of synthetic oxytocin. This is expected to create growth opportunities for market players. The Tier 1 companies are expected to account for 35% to 40% of the overall sales in the market,” says the Future Market Insights analyst.

Key Takeaways from Oxytocic Pharmaceuticals Market Survey

  • In terms of indication, post-partum hemorrhage segment will register fastest growth, with a market attractiveness index of 3.9 through 2031
  • Sales in synthetic oxytocic pharmaceuticals segment will total US$ 207.80 Mn by 2031-end
  • China oxytocic pharmaceuticals market will expand at a CAGR of 9.8% during the forecast period
  • Japan oxytocic pharmaceuticals market will surpass a valuation of US$ 1.7 Mn on the back of growing birth rate across the country
  • Hospitals will be the primary end user in the oxytocic pharmaceuticals market, exhibiting growth at over 12% CAGR
  • India will account for over 60% of Asia Pacific excluding Japan’s oxytocic pharmaceutical sales by 2031-end
  • Over 22,000 thousand units of oxytocic pharmaceuticals will be sold for treating labor arrest during the forecast period

Key Drivers

  • Increasing prevalence of post-partum hemorrhage among older women will boost the market growth during the forecast period
  • Growing awareness regarding induced labor and breastfeeding among consumers will spur the growth of oxytocic pharmaceuticals market

Key Restraints

  • High cost of oxytocin drug is likely to hamper the growth of oxytocic pharmaceuticals market
  • Availability of alternative drugs such as magnesium sulphate and misoprostol will restrict the demand

Ask an Analyst @

Competitive Landscape

Presence of numerous local players in the market has led to market fragmentation. Key companies such as Pfizer, Novartis, and Teva Pharmaceuticals Industries are focusing on product launches and research & development activities.

Strategic mergers and collaborations are also on the card for leading players to expand their regional footprints.

In August 2021, ObsEva SA, a global biopharmaceutical company developing and commercializing novel therapies to improve women’s health, announced the publication and clinical trial on oxytocin receptor antagonist in development for improving live births in women undergoing embryo transfer following in-vitro fertilization (IVF).

Some of the leading players operating in the oxytocic pharmaceuticals market profiled by Future Market Insights are:

  • Fresenius Kaci AG
  • Biofutura SPA
  • Baxter Healthcare Corporation
  • Pfizer Inc.
  • Ferring BV
  • Novartis AG
  • Teva Pharmaceuticals Industries Ltd.
  • Others

More Valuable Insights on Market

Future Market Insights provides an unbiased analysis of the oxytocic pharmaceuticals market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global oxytocic pharmaceuticals market with a detailed segmentation on the basis of:

By Indication:

  • Abortion Induced Incomplete
  • Inevitable Abortion
  • Post-partum Hemorrhage
  • Labor Induction
  • Labor Arrest

By Route of Administration:

  • Intravenous Infusion/Injection
  • Intramuscular Injection

By Source of Origin:

  • Natural Oxytocin
  • Synthetic Oxytocin Derivative

By End-Users:

  • Hospitals
  • Maternity Clinics

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific Excluding Japan and China (APEJC)
  • Japan
  • China
  • Middle East & Africa (MEA)

Report Customization available @

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of the Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favour the market growth in various segments based on Source, Application, Sales Channel and End-Use over the next 10-years.


Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries:



Editor Details

Last Updated: 12-Jul-2022